The study uses several cancer medicines, depending on the specific change found in the tumor. These include olaparib, erlotinib, crizotinib, trametinib, pemigatinib, selpercatinib, axitinib, vismodegib, pembrolizumab, larotrectinib, dabrafenib, and the injection Phesgo (trastuzumab and pertuzumab). Standard care medicines in the study include oxaliplatin, capecitabine, irinotecan, fluorouracil, calcium folinate, gemcitabine, and paclitaxel albumin-bound. Some medicines are taken by mouth, while others are given by injection or infusion into a vein.

During the study, people are assigned to receive either the tailored treatment or standard care. Treatment is given in repeated cycles, with regular medical visits to check health, side effects, and how the cancer is doing. The study follows people over time to see how long the cancer stays under control and how the treatments compare in safety and overall benefit.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The purpose of the study is to find out if ponsegromab can help people gain body weight, improve appetite-related symptoms, and see if it is safe to use. During the study, participants will receive either ponsegromab or placebo along with their regular chemotherapy treatment. The study will measure changes in body weight, appetite symptoms, physical activity levels, and body composition using CT scan or MRI imaging. The study will also look at how the cancer responds to treatment and track overall survival and quality of life measures. Participants will be monitored for side effects and any changes in their health throughout the study period.

The study will last for several years and includes regular visits where measurements will be taken at different time points, with an important assessment at week 12. The study also includes an open-label extension phase where participants may continue to receive ponsegromab. Throughout the study, doctors will check body weight, muscle mass, fat tissue, physical activity, fatigue levels, and overall well-being using questionnaires and physical measurements.

Participants in the study will receive the treatment M9140 through an intravenous infusion, which means it will be given directly into a vein. The study will observe how the cancer responds to the treatment and will also monitor any side effects that participants might experience. The study is designed to understand the treatment’s effectiveness and safety over a period of time.

The trial will help determine the clinical activity of M9140 by measuring the objective response, which refers to how much the cancer shrinks or disappears after treatment. Other aspects being studied include the duration of response, progression-free survival, and any adverse events related to the treatment. This research aims to provide valuable information about the potential benefits of M9140 for people with advanced pancreatic cancer.

The purpose of the study is to assess the safety and tolerability of these treatments in patients with advanced or metastatic PDAC. The study will be conducted in two phases. In the first phase, the focus will be on determining how safe the treatments are and how well patients can tolerate them. In the second phase, the study will continue to monitor safety and will also look at how effective the treatments are in fighting the cancer. Patients will receive the treatment through an IV infusion, which means the medicine is given directly into a vein.

Throughout the study, patients will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to find out if these new treatments can help control the cancer and improve the quality of life for patients with PDAC. The trial will also explore how long the modified T-cells stay active in the body and how they affect the cancer over time. This research is important for developing new ways to treat pancreatic cancer, especially for those with specific genetic markers like the KRAS mutation.

The purpose of this study is to evaluate the safety of using the combination of modFOLFIRINOX and TTFields as a first-line treatment for patients with this type of cancer. Participants in the study will receive the treatment and be monitored for any side effects or adverse reactions. The study will also track how long patients can go without the cancer getting worse, as well as overall survival rates and response to the treatment. The TTFields are delivered using a device called the NovoTTF-200T system, which is designed to disrupt cancer cell division and growth.

Throughout the study, participants will undergo regular assessments to monitor their health and the effectiveness of the treatment. This includes measuring the time the TTFields device is used during each chemotherapy cycle and evaluating the quality of life using a questionnaire. The study aims to provide valuable information on the potential benefits and risks of this treatment approach for individuals with metastatic pancreatic adenocarcinoma.

The purpose of this research is to determine if RMC-6236 is more effective than current standard treatments in improving survival and slowing down disease progression in patients who have already received one previous treatment for their metastatic pancreatic cancer. The study specifically looks at patients whose tumors have certain genetic changes called RAS mutations.

During the study, participants will be randomly assigned to receive either RMC-6236 tablets or one of the standard treatment options given through intravenous infusion. The effectiveness of the treatments will be measured by how long patients live and how long they live without their cancer getting worse.

The purpose of the study is to evaluate the safety and effectiveness of ginisortamab in combination with other treatments. In the first part of the study, participants will receive ginisortamab along with standard cancer treatments, nab-paclitaxel and gemcitabine, which are commonly used chemotherapy drugs. In the second part, ginisortamab will be combined with a MEK inhibitor, a type of medication that helps prevent cancer cells from growing, as a maintenance therapy for those who have responded well to initial treatment.

Participants in the study will receive these treatments over a period of time, and researchers will monitor them to assess the safety of ginisortamab and its ability to control the cancer. The study aims to find the best dose of ginisortamab and to observe any potential anti-cancer effects. The trial will help determine if ginisortamab can be a beneficial addition to existing treatment options for this type of cancer.

The purpose of this study is to determine which treatment combination is more effective in delaying the progression of the cancer. Participants in the study will receive one of the two treatment combinations. The treatments are administered through intravenous infusion, which means they are given directly into a vein, or in the case of S-1, taken orally as capsules. The study will monitor the participants over a period to see how the cancer responds to the treatments and to assess any side effects or changes in quality of life.

Throughout the study, researchers will focus on measuring how long the cancer can be kept from getting worse, known as progression-free survival. They will also look at overall survival rates, how well the cancer responds to the treatments, any side effects experienced, and the impact on the participants’ quality of life. This information will help determine the best treatment option for patients with metastatic pancreatic cancer who have not had success with gemcitabine-based chemotherapy.

The purpose of the study is to compare the effects of the combination of Napabucasin, Paclitaxel, and Gemcitabine with standard treatment options. Participants will receive these medications through an infusion, which means the drugs are delivered directly into the bloodstream through a vein. The study will be conducted in two phases. In the first phase, the focus will be on how long patients can live without the cancer getting worse and the safety of the treatment. In the second phase, the study will look at the overall survival of patients, which means how long they live after starting the treatment.

Participants in the study will be randomly assigned to receive either the investigational treatment or a standard treatment. The study will continue for several years, and patients will be monitored regularly to assess their health and the effects of the treatment. The goal is to find out if the new combination of drugs can help improve outcomes for people with metastatic pancreatic cancer after other treatments have failed.

The purpose of the study is to evaluate the effectiveness and safety of this combination of treatments in patients who have not received prior treatment for their metastatic pancreatic cancer. Participants in the study will receive these treatments over a period of time, and their response to the treatment will be closely monitored. The study aims to understand how well the cancer responds to the treatment and to assess any side effects that may occur.

Throughout the study, participants will receive regular infusions of the medications, and their health will be monitored by healthcare professionals. The study will help determine if this combination of treatments can improve outcomes for patients with metastatic pancreatic cancer. The results of this study could provide valuable information for future treatment options for this challenging disease.

The purpose of this study is to evaluate the safety and effectiveness of combining these two treatments in patients with metastatic pancreatic cancer. The study will begin with a phase to ensure the combination is safe for patients, followed by a phase to assess how well the treatment works. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor patients over time to see how the cancer responds to the treatment and to check for any side effects.

Throughout the study, various aspects will be observed, such as overall survival, which is the length of time patients live after starting the treatment, and progression-free survival, which is the time during which the cancer does not get worse. The study will also look at changes in the immune system and the quality of life of the participants. This research aims to provide valuable information on the potential benefits of using durvalumab and rintatolimod together for treating metastatic pancreatic cancer.

The purpose of the study is to evaluate the safety and effectiveness of this combined treatment. Initially, a small group of patients will receive the treatment to ensure it is safe. If the treatment is found to be safe, more patients will be included to further assess how well it works in controlling the cancer. The study aims to see if this combination can improve the time patients live without the cancer getting worse.

Participants in the study will receive the IMM-101 injections along with SBRT. The study will monitor the patients’ overall health, the progression of their cancer, and their quality of life throughout the treatment. The goal is to determine if this new approach can offer better outcomes for patients with limited metastatic pancreatic cancer.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Olaparib and are still benefiting from it. The study aims to ensure the safety and tolerability of the ongoing treatment. Patients will continue to receive Olaparib if they are judged by their doctor to be benefiting from the treatment. The study will monitor the patients’ health and any side effects that may occur during the treatment period.

Participants in this study will take Olaparib tablets orally, with the treatment period lasting up to 123 days. The study will keep track of any serious side effects or important medical events that happen up to 30 days after the last dose of the study drug. This trial is designed to help patients who are already experiencing positive effects from Olaparib to continue their treatment safely.

Participants in the study will receive the chemotherapy drugs through an intravenous infusion, which means the medicine is given directly into a vein. This treatment will be given over a period of time before the planned surgery to remove the cancer. The study aims to find out if this approach can help improve the chances of successfully removing the cancer and to understand the effects on the patients’ quality of life.

The study will also look at how safe the treatment is and monitor any side effects that may occur. The goal is to determine if this treatment can help patients live longer and improve their quality of life. The study is open-label, meaning both the researchers and participants know what treatment is being given, and it is a single-arm study, which means all participants receive the same treatment without a comparison group. A placebo is not used in this study.

Participants in the study will be randomly assigned to one of two groups. One group will receive the standard chemotherapy treatment, while the other group will receive the standard treatment plus VCN-01. The VCN-01 is given through an intravenous infusion, which means it is delivered directly into the bloodstream. The study will monitor patients over a period of time to assess the safety and tolerability of VCN-01, as well as its impact on survival.

The trial aims to provide valuable information on whether VCN-01 can be a beneficial addition to the current treatment options for metastatic pancreatic cancer. By participating in this study, researchers hope to gather data that could lead to improved treatment strategies for this challenging disease.

The purpose of this study is to determine the best dose of mitazalimab when used with chemotherapy and to assess how well this combination works against the cancer. The study is divided into different parts. In the first part, researchers will find the most suitable dose of mitazalimab to use in further testing. In the later parts, they will evaluate how effective the treatment is in shrinking the cancer or stopping it from growing. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information on the safety and effectiveness of mitazalimab combined with chemotherapy for treating metastatic pancreatic ductal adenocarcinoma. This research could potentially lead to new treatment options for patients with this type of cancer.

The purpose of this study is to find out how safe and effective the combination of ABTL0812 and FOLFIRINOX is for treating metastatic pancreatic cancer. The study is divided into two phases. In the first phase, researchers will focus on the safety of the treatment combination. In the second phase, they will compare the effectiveness of ABTL0812 with FOLFIRINOX against FOLFIRINOX with a placebo. The study will look at how long patients live without the cancer getting worse, which is known as progression-free survival.

Participants in the study will receive either the new treatment combination or the standard treatment with a placebo. The study will monitor the participants’ health and response to the treatment over time. This research aims to provide new insights into potential treatments for metastatic pancreatic cancer, offering hope for improved outcomes for patients with this challenging condition.

The purpose of the study is to determine if the combination of these medications can improve the effectiveness of the standard treatment, which includes gemcitabine and nab-paclitaxel. Participants in the study will be randomly assigned to receive either the standard treatment or the new combination of medications. The study will monitor how long patients live without the cancer getting worse, as well as other factors like tumor response, overall survival, and quality of life. Blood samples will also be collected to study how the body processes the drugs and to look for markers that might predict how well the treatment works or what side effects might occur.

The study will take place over several months, with regular check-ups and assessments to track the progress of the disease and the effects of the treatment. The goal is to find a more effective treatment option for patients with metastatic pancreatic ductal adenocarcinoma, potentially improving their quality of life and survival rates. Participants will receive either the new combination of medications or the standard treatment, and their health will be closely monitored throughout the study period.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

Participants in the study will first receive the combination of FOLFIRINOX, pembrolizumab, and SABR. After this initial treatment, patients will undergo surgery to remove the cancer if possible. Following surgery, patients will receive more FOLFIRINOX and pembrolizumab to help prevent the cancer from returning. The study aims to see if this approach can help patients live longer without the cancer progressing.

The study will also look at other important outcomes, such as overall survival, the success rate of surgeries, and the side effects of the treatments. Additionally, it will assess the quality of life of participants and how well they respond to the treatments. This trial is part of ongoing research to find better ways to treat pancreatic cancer and improve outcomes for patients with this challenging disease.

The purpose of this study is to evaluate whether adding TTX-030, with or without Budigalimab, to the standard chemotherapy regimen can improve outcomes for patients who have not received prior treatment for their metastatic pancreatic cancer. Participants in the study will be randomly assigned to one of three groups: one group will receive TTX-030 and chemotherapy, another group will receive TTX-030, Budigalimab, and chemotherapy, and the third group will receive only the chemotherapy. The study will monitor participants over a period of time to assess the progression of the disease and any side effects experienced.

Throughout the study, participants will receive their assigned treatments through intravenous infusion, which means the medication will be delivered directly into a vein. The study aims to provide valuable information on whether these new treatment combinations can help manage metastatic pancreatic cancer more effectively than the current standard chemotherapy alone. Participants will be closely monitored by healthcare professionals to ensure their safety and to gather data on the treatment’s impact on their cancer.

The purpose of the study is to determine if the combination of zolbetuximab with nab-paclitaxel and gemcitabine can help patients live longer compared to using nab-paclitaxel and gemcitabine alone. The study will also look at how safe and tolerable the new treatment is for patients. Participants in the study will be randomly assigned to receive either the new combination treatment or the standard chemotherapy treatment. The study will monitor the participants’ health and response to the treatment over a period of time.

Throughout the study, participants will receive the treatment through an intravenous infusion, which means the medication will be given directly into a vein. The study will also involve regular check-ups and tests to monitor the participants’ health and the effects of the treatment. The goal is to gather information that could lead to better treatment options for people with metastatic pancreatic adenocarcinoma in the future.

The purpose of this study is to determine how well patients respond to this combination treatment over a twelve-week period. Specifically, researchers want to see if the treatment can stop or slow down the progression of cancer during this time. The treatment period may last up to 12 months, during which patients will receive regular medical check-ups and imaging scans to monitor their condition.

During the study, patients will take both medications daily according to a specified schedule. Trametinib will be given at doses up to 2 mg per day, while hydroxychloroquine will be administered at doses up to 1200 mg per day. Doctors will monitor patients throughout the study to check for any side effects and to evaluate how well the treatment is working.

The purpose of the study is to assess the safety and potential benefits of these treatments in patients with advanced solid tumors. The study is divided into two parts. In the first part, researchers will focus on understanding how safe and tolerable the combination of ICT01 and low-dose interleukin-2 is, both with and without pembrolizumab. In the second part, the study will look at how well these treatments work in controlling the cancer. Patients will receive the treatments and be monitored for any side effects and changes in their cancer status.

Participants in the study will receive the treatments over a period of time and will have regular check-ups to monitor their health and the progress of their cancer. The study aims to gather information on how the cancer responds to the treatments and any side effects that may occur. This information will help determine if these treatment combinations could be beneficial for patients with these types of advanced cancers in the future.

The purpose of this study is to evaluate the safety and side effects of the treatment combination and to see how well it works in treating pancreatic cancer. Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted in phases, starting with the combination of immunotherapy and chemotherapy, followed by the addition of radiation therapy. Throughout the study, participants will undergo regular medical imaging tests, such as MRI or CT scans, to monitor the cancer’s response to the treatment. These imaging tests help doctors see inside the body and check how the cancer is reacting to the treatment.

The study aims to provide valuable information about the potential benefits and risks of this treatment approach for pancreatic cancer. By combining different types of therapies, researchers hope to improve the effectiveness of treatment and offer new options for patients with this challenging disease. The study will continue until 2026, with the goal of gathering comprehensive data on the treatment’s impact on patients’ health and quality of life.

The purpose of the study is to evaluate the safety and effectiveness of combining pelareorep and atezolizumab with standard chemotherapy treatments. Participants will receive these treatments and be monitored for their response to the therapy. The study will assess how well the combination of these drugs works in treating the cancer and how well patients tolerate the treatment. The study will also look at the overall response rate, which measures how the cancer responds to the treatment, and the disease control rate, which indicates how well the treatment keeps the cancer from growing or spreading.

Throughout the study, participants will undergo regular assessments to monitor their health and the effects of the treatment. These assessments will include checking for any side effects and measuring the size of the cancer to see how it responds to the treatment. The study aims to provide valuable information on the potential benefits of using pelareorep and atezolizumab together with standard chemotherapy for treating advanced gastrointestinal cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

The purpose of the study is to evaluate how well these treatments control the disease. Participants will receive the treatments and be monitored to see if the cancer remains stable, shrinks, or disappears. The study will also look at how long participants live after starting the treatment. The study will last for a period of time, and participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The goal is to gather information on how effective the combination of TTFields, atezolizumab, gemcitabine, and nab-paclitaxel is in treating metastatic pancreatic ductal adenocarcinoma. This information could help improve treatment options for this type of cancer in the future.

The purpose of the study is to evaluate which treatment is more effective in improving the overall survival of patients who have not previously received chemotherapy for their metastatic pancreatic cancer. Participants in the study will be randomly assigned to receive one of the two treatment regimens. The study will monitor the participants over a period to assess their response to the treatment and any side effects they may experience.

Throughout the study, participants will receive regular medical check-ups and tests to track their health and the progress of their cancer. The study will also look at other outcomes, such as how long the cancer stays under control and the overall response rate to the treatments. This research is important for understanding which treatment option may offer better outcomes for patients with metastatic pancreatic cancer.

The purpose of the study is to compare the effectiveness of these treatments in patients with metastatic pancreatic cancer. Participants will be randomly assigned to one of three groups. One group will receive a combination of Nal-IRI and 5FU/LV, another group will receive gemcitabine and Nab-paclitaxel, and the third group will receive a sequential regimen starting with 5FU/LV and Nal-IRI for two months, followed by gemcitabine and Nab-paclitaxel for another two months. The study will last for up to 12 months, and participants will receive their treatments through an intravenous infusion, which means the medication is given directly into a vein.

The main goal is to see how long patients can live without their cancer getting worse over a period of six months. The study will also look at other factors, such as the overall survival of patients, the response of the tumors to the treatment, and the quality of life of the participants. This information will help doctors understand which treatment combinations might work best for people with metastatic pancreatic cancer.

Participants in the study will be divided into groups to receive either the immediate or delayed start of chemotherapy. The study will monitor the participants over a period to assess their overall survival and quality of life. The trial will also look at how long it takes for the disease to progress and any side effects experienced by the participants. The goal is to determine the best timing for starting chemotherapy to improve the quality of life and survival for patients with metastatic pancreatic cancer.

The study will continue until 2027, and it will gather data on various outcomes, including the time without symptoms or side effects and changes in specific cancer markers. This information will help doctors make informed decisions about the timing of chemotherapy for patients with this type of cancer. Participants will be closely monitored throughout the study to ensure their safety and well-being.